ArriVent BioPharma, Inc. filed a Form 8-K on November 9, 2026, disclosing the planned retirement of President of Research and Development Stuart Lutzker, M.D., Ph.D., effective December 1, 2026, along with the appointment of Chief Medical Officer Priti Patel, M.D., to lead the company's research and development function on the same date.

Key Highlights

  • Retirement notice: Stuart Lutzker, M.D., Ph.D. notified ArriVent BioPharma on November 6, 2026, of his intention to retire as President, Research and Development and as a director, effective December 1, 2026.
  • Retirement payment: Under the planned retirement agreement, the company intends to pay Dr. Lutzker a one-time payment of $428,438.21, subject to conditions including performance of duties, compliance with restrictive covenants, and a release of claims.
  • No disagreement: According to the filing, Dr. Lutzker's departure "was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies, or practices."
  • Patel assumes R&D leadership: Priti Patel, M.D., age 51, the company's Chief Medical Officer, will assume responsibility for leading the research and development function effective December 1, 2026.
  • Patel's background: Dr. Patel previously served as Chief Medical Officer of Neoleukin Therapeutics (May 2021 to April 2023) and as Vice President and Head of Hematology Clinical Development at AstraZeneca, before joining ArriVent in January 2026.
  • Q3 2026 results: The company also issued a press release on November 9, 2026, announcing financial results for the third quarter ended September 30, 2026, furnished as Exhibit 99.1.

ArriVent BioPharma Discloses Leadership Transition in Research and Development

ArriVent BioPharma, Inc. (NASDAQ:AVBP) reported in its November 9, 2026 Form 8-K that Stuart Lutzker, M.D., Ph.D., gave notice on November 6, 2026, of his retirement from his roles as President, Research and Development and as a member of the company's board of directors. His retirement is set to take effect on December 1, 2026, which the filing designates as the "Retirement Date." The filing stated that the departure was not the result of any disagreement with the company on any matter relating to its operations, policies, or practices.

According to the filing, the company intends to enter into a retirement agreement with Dr. Lutzker that would provide a one-time payment of $428,438.21. The filing described the payment as consideration for, among other things, Dr. Lutzker's performance of duties requested by the company until the Retirement Date, his compliance with certain restrictive covenants, and a release of claims. The retirement agreement had not yet been executed as of the filing date.

In connection with Dr. Lutzker's departure, the filing disclosed that Priti Patel, M.D., age 51, the company's current Chief Medical Officer, will assume the role of leading the research and development function effective December 1, 2026. The filing described Dr. Patel as having expertise in clinical development, oncology, and hematology drug development. Before joining ArriVent in January 2026, she served as an independent consultant to biotechnology companies from April 2023 to January 2026, and previously held the role of Chief Medical Officer at Neoleukin Therapeutics from May 2021 to April 2023. She also served as Vice President and Head of Hematology Clinical Development at AstraZeneca, following earlier roles at Acerta Pharma B.V., an AstraZeneca group company. The filing noted no transactions requiring disclosure under Item 404(a) of Regulation S-K and no family relationships between Dr. Patel and any directors or executive officers of the company.

What Was Disclosed

ArriVent BioPharma disclosed the planned retirement of its President of Research and Development, a one-time retirement payment of $428,438.21, and the transition of R&D leadership to Chief Medical Officer Priti Patel, M.D., all effective December 1, 2026. The company also reported Q3 2026 financial results via a furnished press release.